OSLO, Norway--(BUSINESS WIRE)--DiaGenic ASA today presented preliminary results at The Federation of Obstetrics and Gynecology Societies of India (F.O.G.S.I ) annual meeting in New Delhi from the study it is conducting in India using its early breast cancer gene expression blood test. The results from the first 113 patients show that the gene expression signature, previously identified in Scandinavian and US cohorts, shows good diagnostic performance in an Indian population. Preliminary data shows similar levels of accuracy obtained with the European/US cohorts as for the Indian cohort. DiaGenic now aims to complete the study of 720 subjects in the next few months and is in dialogue with local partners to market the test in India.
